Ablynx to receive milestone payment from Novartis
NVS | Quote | Chart | News | PowerRating -- Ablynx, a Belgian biopharmaceutical company, has reported that it will receive an undisclosed milestone payment from Swiss pharmaceutical group Novartis.
The payment has been triggered by successful delivery to Novartis of Nanobody candidates which met specific criteria. This will be the third milestone payment that Ablynx has received from Novartis since the initiation of the alliance between the companies.
Novartis and Ablynx have entered into the alliance in December 2005 to discover and develop therapeutic Nanobodies against targets that are difficult to address with conventional antibodies and fragments.
Under the terms of this ongoing agreement, Ablynx receives upfront fees, license fees and funding for R&D. In addition, Ablynx is eligible for milestone payments and royalties upon commercialization. Novartis has exclusive rights to develop and commercialize the Nanobody products resulting from the collaboration.
Edwin Moses, CEO and chairman of Ablynx, said: "This is an important stage in our alliance with Novartis as these Nanobodies have shown significant activity in vivo compared with an antibody. We are very pleased with the progress made and look forward to reaching further key milestones under this alliance in the future."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on Novartis Ag Ads (NVS) NVS. Novartis Ag Ads (NVS) has Short Term PowerRatings at TradingMarkets. Details on Novartis Ag Ads (NVS) Short Term PowerRatings is available at This Link.
- Lupin wins FDA approval for hypertension drug - 02/10/10
- Debiopharm Group signs agreement with Novartis for Debio 025 - 02/09/10
- SciClone and Sigma-Tau reports positive results from influenza vaccine study - 02/09/10
- Debiopharm Group signs licensing agreement with Novartis for Debio 025 for hepatitis C - 02/09/10
- Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 - 02/09/10
- More News >>


